ReviewCancers2021
Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Development and validation of a prognostic nomogram based on the clinical indicators for breast cancer.Gland surgery · 2026Article
- Article
- Neoadjuvant chemotherapy is not necessarily applicable to patients with LN1-3 positive Luminal-B type operable breast cancer.Scientific reports · 2025Article
- Expression of Fascin and DNA Topoisomerase 2-Alpha in Breast Carcinoma: Correlation with Histological Subtypes and Other Prognostic Markers.International journal of molecular sciences · 2025Article
- TMPO-AS1-hsa-let-7b-5p-EZH2-RNA network predicts poor survival in basal-like breast cancer patients.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Article
- Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer.Cancers · 2024Review
- Smart Biosensor for Breast Cancer Survival Prediction Based on Multi-View Multi-Way Graph Learning.Sensors (Basel, Switzerland) · 2024Article
- Analytical validation and algorithm improvement of HepatoPredict kit to assess hepatocellular carcinoma prognosis before a liver transplantation.Practical laboratory medicine · 2024Article
- Enhancing cancer stage prediction through hybrid deep neural networks: a comparative study.Frontiers in big data · 2024Article
- Review
- Article
- Applying a GAN-based classifier to improve transcriptome-based prognostication in breast cancer.PLoS computational biology · 2023Article
- PROCURE European consensus on breast cancer multigene signatures in early breast cancer management.NPJ breast cancer · 2023Article
- The characteristics and clinical significance of atypical mitosis in breast cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Particle swarm optimization artificial intelligence technique for gene signature discovery in transcriptomic cohorts.Computational and structural biotechnology journal · 2022Article
- Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights.Cancer management and research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of gene expression signatures since the early 2000's has offered standardized assays to evaluate the prognosis of early breast cancer. Five signatures are currently commercially available and recommended by several international guidelines to individualize adjuvant chemotherapy decisions in hormone receptors-positive/HER2-negative early breast cancer. However, many questions remain unanswered about their predictive ability, reproducibility and external validity in specific populations. They also represent a new hope to tailor (neo)adjuvant systemic treatment, adjuvant radiation therapy, hormone therapy duration and to identify a subset of patients who might benefit from CDK4/6 inhibitor adjuvant treatment. This review will highlight these particular issues, address the remaining questions and discuss the ongoing and future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.